Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price dropped 4.6% during mid-day trading on Thursday . The company traded as low as $21.90 and last traded at $21.63. Approximately 10,387 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 310,105 shares. The stock had previously closed at $22.66.

Analyst Ratings Changes

A number of equities analysts have commented on DNTH shares. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Oppenheimer raised their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. TD Cowen started coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Stock Down 4.8 %

The firm has a fifty day simple moving average of $23.16 and a two-hundred day simple moving average of $26.23.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp boosted its holdings in shares of Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Dianthus Therapeutics by 40.5% during the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock worth $25,936,000 after purchasing an additional 273,670 shares in the last quarter. Point72 Asset Management L.P. raised its position in shares of Dianthus Therapeutics by 151.3% during the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after buying an additional 263,500 shares during the last quarter. Braidwell LP lifted its stake in Dianthus Therapeutics by 34.6% in the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after purchasing an additional 126,836 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after buying an additional 97,362 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.